AUPH — Aurinia Pharmaceuticals Inc.

Open full analysis

Chart, dilution, float and news for AUPH in the TickerWise workspace.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: CA
• Exchange: NASDAQ
• Employees: 130
• Website: https://www.auriniapharma.com

Latest SEC filings for AUPH

• 2026-08-068-K
• 2026-08-0610-Q
• 2026-06-048-K
• 2026-05-118-K
• 2026-05-078-K
• 2026-05-0710-Q
• 2026-04-038-K
• 2026-03-238-K
• 2026-02-2610-K
• 2026-02-268-K

Latest AUPH news

• 2026-10-23Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term Read article
• 2026-10-12Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL) Read article

Open full analysis

Educational tool only — not investment advice.